ReviewHealthcare (Basel, Switzerland)2025
Reproductive and Fertility Care of Women with Schizophrenia: A Narrative Review.
Review in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with schizophrenia have specific reproductive and fertility care needs that differ from those of men. This narrative review aims to explore the reproductive and fertility care needs of women with schizophrenia related to fertility, menstrual cycle, family planning, and the perinatal period. Hormonal fluctuations in the menstrual cycle can significantly affect clinical symptoms and the efficacy of contraceptive treatments in women with schizophrenia. When undergoing fertility treatment, attention should be given to the potential interactions between fertility treatment drugs and antipsychotics, as well as the potential impact of antipsychotics on the ability to conceive. Although pregnancy rates and participation in fertility programs have increased among women with schizophrenia, very little information is available on the safety and efficacy of fertility treatments in women with severe psychotic disorders. This is an area that warrants further study. Mobilizing social supports and optimizing medication are important components of the treatment of schizophrenia in the perinatal period and are important for the health and safety of infants and mothers. In conclusion, preventing relapse and promoting physical and mental health in this group of women during successive reproductive periods of life is vital and requires an emphasis on the social and psychiatric context, as well as the biological changes occurring at these times.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.